ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 675

Differential Impairment of Serum Cholesterol Efflux Capacity in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus

Pier Luigi Meroni1, Nicoletta Ronda2, Elda Favari3, Orietta Borghi4, Francesca Zimetti5, Mariapia Adorni6, Francesca Ingegnoli7, Maria Gerosa8, Claudia Grossi9 and Franco Bernini6, 1Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, 2Department of Pharmacy, University of Parma, Parma, Italy, 3Department of Pharmacological and Biological Sciences,, University of Parma, Parma, Italy, 4Department of clinical and comunity sciences, University of Milan, Milan, Italy, 5Department of Pharmacological and Biological Sciences, University of Parma, Parma, Italy, 6Department of Pharmacological and Biological Sciences, 39-02-58318176, Parma, Italy, 7Dept. of clinical and community science, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, 8Department of Clinical Sciences and Community Health, University of Milan, Italy, Division of Rheumatology, Istituto Ortopedico Gaetano Pini,, Milan, Italy, 9Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Accelerated atherosclerosis associated with autoimmune diseases is partly due to immune system dysregulation aggravating cardiovascular damage, but little is known on lipid metabolism derangement in this condition. Serum capacity to promote cholesterol efflux from macrophages (CEC) is the first limiting step of the atheroprotective reverse cholesterol transfer process, mainly reflects HDL function and inversely correlates to subclinical atherosclerosis in vivo. Moreover, the relevance of CEC is strengthened by recent evidence of an impact of cholesterol efflux on inflammatory and immune functions of macrophages and endothelial cells. We measured  the four main CEC pathways in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.

Methods: aqueous diffusion (AD)-, SR-BI-, ABCG1- and ABCA1-mediated CEC was measured by validated radioisotopic ex vivo systems in 30 AR and 30 SLE patients, and in 30 age and sex-matched healthy subjects.

Results: SR-BI-mediated CEC (mean±SEM % efflux) was increased in SLE patients (3.84±0.19) as compared to controls (3.20±0.20) and RA patients (2.78±0.17). ABCG1-mediated CEC was reduced in RA and more markedly in SLE (6.04±0.25 and 4.36±0.34, respectively) as compared to controls (7.13±0.2%). ABCA1-mediated CEC was impaired in SLE (2.55±0.16) as compared to controls and RA patients (3.14±0.19 and 3.54±0.30, respectively). AD-mediated CEC did not differ between the three populations studied. ABCG1-mediated CEC inversely correlated with the disease activity score DAS28 in RA patients. SLE patients as a group showed the lowest ABCG1-mediated CEC in spite of the highest HDL serum level. The correlation between ABCG1-mediated CEC and serum HDL, detected in controls and in SLE patients, was absent in RA. The correlation between ABCG1-mediated and SR-BI-mediated CEC detected in controls and RA patients was absent in SLE.

Conclusion: we report here for the first time a marked and differential CEC impairment in patients with RA and SLE, independent of HDL serum levels, that not only demonstrates a dysfunction and loss of atheroprotective activity of HDL with respect to cholesterol metabolism, but also points to the existence of specific underlying mechanisms in each disease, possibly beyond inflammation. Moreover, the impairment of ABCG1-mediated cholesterol efflux in autoimmune patients, that correlated with disease activity in the RA group, might also have an impact in inflammatory and immune reaction involving macrophages and endothelial cells.


Disclosure:

P. L. Meroni,
None;

N. Ronda,
None;

E. Favari,
None;

O. Borghi,
None;

F. Zimetti,
None;

M. Adorni,
None;

F. Ingegnoli,
None;

M. Gerosa,
None;

C. Grossi,
None;

F. Bernini,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-impairment-of-serum-cholesterol-efflux-capacity-in-patients-with-rheumatoid-arthritis-and-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology